Abstract
Introduction
The present study aimed to examine the functions of heat shock protein 90 (HSP90), NF-κB, C3, and C5a in cardioprotective effects induced by vericiguat in mice.
Methods
Male mice were randomly assigned to six groups: sham, ischemia/ reperfusion (I/R), vericiguat preconditioning (VPre), VPre + HSP90 inhibitor geldanamycin (GA), vericiguat postconditioning (VPost), and VPost + GA. An experimental mouse model of I/R was established in mice through surgery and treatments with vericiguat and GA. The following parameters were assessed: myocardial infarct size; cardiomyocyte apoptosis; cTnI, CK-MB, and LDH serum levels, protein expression levels of Bcl-2, Bax, HSP90, NF-κB, and complement components C3 and C5a, and mRNA expression levels of IL-1β, TNF-α, and ICAM-1.
Results
Vericiguat significantly attenuated the myocardial infarct size induced by I/R injury; suppressed cardiomyocyte apoptosis; reduced serum levels of myocardial markers (CK-MB, LDH, and cTnI); decreased C5a, and C3 levels, NF-κB signaling, and expression of inflammatory cytokine (ICAM-1,TNF-α, and IL-1β); and enhanced HSP90 and Bcl-2 expression levels. However, GA reversed these effects.
Discussion
The study contributes to the investigation of the crosstalk between HSP90 and complement in the protective effects of vericiguat on myocardial I/R injury. However, further in-depth research is needed to explore the underlying mechanisms of vericiguat's cardioprotective effects against myocardial I/R injury.
Conclusion
HSP90 plays a crucial role in the cardioprotective effects of vericiguat, providing new insights into its mechanisms of action.
Keywords: Vericiguat, myocardial ischemia/reperfusion injury, HSP90, complement, inflammation, apoptosis, mice
1. INTRODUCTION
Acute myocardial infarction (AMI) is the primary cause of mortality and disability worldwide [1]. Currently, reperfusion therapies, including percutaneous coronary intervention, coronary artery bypass grafting, and thrombolytic therapy, remain the most effective methods to treat myocardial infarction. However, reperfusion can cause additional damage to the ischemic myocardium. This phenomenon, known as ischemia/reperfusion (I/R) injury, can potentially aggravate myocardial damage [2]. Therefore, identifying methods and strategies to mitigate I/R injury remains a critical topic in treating AMI [3]. The cardioprotective effects of soluble guanylate cyclase (sGC) stimulants on I/R injuries have garnered significant attention in recent years [4].
sGC stimulants are recently discovered new drugs for treating cardiovascular diseases, and they function by activating the nitric oxide (NO)-sGC-cyclic guanosine phosphate (cGMP) pathway. The VICTORIA trial, the largest clinical study of sGC stimulants globally, revealed that vericiguat enhances outcomes in patients with heart failure and shows beneficial results in patients with coronary heart disease [5, 6]. Multiple studies have reported that vericiguat ameliorates myocardial I/R injury [4, 7]. However, the precise mechanisms through which vericiguat protects the heart during myocardial I/R injury remain incompletely understood.
Complement activation has been established as a significant contributor to myocardial I/R injury [8]. Complement components C3 and C5a initiate a cascade of pro-inflammatory cells, leading to the release of inflammatory mediators, including intercellular cell adhesion factor-1 (ICAM-1), tumor necrosis factor-α (TNF-α), and interleukin (IL)-1β [9-11]. Additionally, excessive activation of the complement system promotes the generation of C3 and C5a, which can activate the NF-κB signaling pathway to aggravate inflammation [12]. Thus, the complement/NF-κB signaling pathway could serve as a potential therapeutic target for treating I/R injury. However, it remains unclear whether vericiguat induces cardioprotective effects through the complement and NF-κB signaling pathway.
Heat shock protein 90 (HSP90) is an essential component of the molecular chaperone network and plays a crucial role in maintaining the integrity and function of multiple signaling proteins and stress response through cardioprotection [13, 14]. Previous research has established a strong relationship between HSP90 and apoptosis during pre- and postconditioning phases [15, 16]. Furthermore, recent reports have shown that HSP90-mediated pre- and post-conditioning induce cardioprotective effects by inhibiting the activation of NF-κB, C3 and C5a signaling [17]. HSP90 exhibits its significant role in the cardioprotective effects of liraglutide, pioglitazone preconditioning, and morphine postconditioning on cardiac I/R injury [18, 19]. However, it remains unclear whether the ability of HSP90 to suppress the activation of C3, C5a, and NF-κB signaling is the primary mechanism that contributes to vericiguat-induced cardioprotective effects.
In the present study, we hypothesized that the cardioprotective effects of vericiguat against myocardial I/R injury are mediated by inhibiting C3, C5a, and NF-κB signaling and suppressing inflammatory responses by up-regulating HSP90 expression. We evaluated the protein levels of NF-κB, HSP90, C3, and C5a and the mRNA levels of TNF-α, IL-1β, and ICAM-1. Additionally, we assessed serum levels of creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), cardiac troponin I (cTnI), and myocardial infarct size, cardiomyocyte apoptosis. The effects of the HSP90 inhibitor geldanamycin (GA) were also investigated.
2. MATERIALS AND METHODS
2.1. Animals
120 male C57BL/6J mice, aged 8-10 weeks (weighing 20 to 25 g), were purchased from the Laboratory Animal Center of Guangxi Medical University, China. The animals were housed at 25°C ± 2°C, with appropriate humidity, a standard 12-h light/dark cycle, and unrestricted access to food and water. All animal experiments complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were ethically approved by the Guangxi Medical University Animal Care and Use Committee (Approval NO.202310009).
2.2. Myocardial I/R Model
Mice were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally) and intubated [20]. A small animal ventilator was used for positive pressure breathing. The chest was accessed through the 4th intercostal space and the left anterior descending (LAD) coronary artery was ligated using a 7-0 silk suture. Successful vascular closure was confirmed by changes in dynamic electrocardiographic ST elevation signals. Ischemia was maintained for 30 min, and the ligature was then released to allow reperfusion for 2 h. The skin of the thoracic cavity was closed using a 5-0 silk suture. Following completion of the reperfusion phase, myocardial tissue samples from the left ventricular anterior wall and blood samples were collected for subsequent analysis.
2.3. Experimental Groups
Mice were randomly allocated to six groups, with 20 mice per group: (1) Sham: the LAD branch alone was threaded without ligation; (2) I/R: the LAD branch was subjected to 30 min of ligation, followed by 2 h of reperfusion; (3) Vericiguat preconditioning (VPre): Mice in the I/R group were administered vericiguat (1 mg/kg) via caudal vein injection 12 h prior to ischemia induction [21]; (4) VPre + GA: Mice in the I/R group were intraperitoneally administered GA (1 mg/kg [22]) 30 min prior to ischemia induction. The subsequent steps followed the same protocol as that for the VPre group; (5) Vericiguat postconditioning (VPost): Vericiguat (1 mg/kg [21]) was administered by caudal vein injection 10min prior to reperfusion initiation, followed by 2 h; (6) VPost + GA: Mice in the I/R group were intraperitoneally administered GA (1 mg/kg [22]) 10 min prior to intravenous vericiguat administration.
2.4. Assessment of Myocardial Infarction Size
Infarct size determination was performed across all six experimental groups. Following 2 h of reperfusion, the LAD coronary artery was again occluded. Subsequently, 2% Evans blue was administered into the left heart cavity. The stained hearts were frozen, cut into 1-inch thick horizontal slices, and incubated for 15 min at 37°C in 2,3,5-triphenyltetrazolium chloride (1%; TTC, Sigma-Aldrich, USA) under light protection to determine the size of the myocardial infarct area. Digital imaging software was used to calculate both infarct size and total left ventricular area.
2.5. Determination of Serum Levels of LDH, CK-MB, and cTnI
Post-reperfusion blood samples were collected in 1.5 mL centrifuge tubes and maintained at room temperature for 30 min, followed by centrifugation at 3000 g for 15 min at room temperature.
The extracted supernatant was stored at -80°C. The cTnI levels were measured using a cTnI ELISA kit (Cusabio, China) in accordance with the manufacturer's instructions on an automated antibody analyzer (Hitachi 7600, Tokyo, Japan). CK-MB and LDH levels were determined using an automated biochemical analyzer (IDEXX Laboratories Inc., Maine, USA).
2.6. TUNEL Staining
Mice were euthanized, and their chest cavities were rapidly accessed to extract the hearts. The hearts were then cleansed with physiological saline and the left ventricular myocardial tissues were excised. Cardiac tissues were fixed with 4% paraformaldehyde, then dehydrated and embedded. A TUNEL kit (Biyun Tian, China) was used for cell staining. Apoptosis was detected by fluorescence microscopy. Five areas were randomly selected from each slide, and the ratio of apoptotic cardiomyocytes to total cardiomyocytes (apoptosis index, %) was calculated using ImageJ software.
2.7. Determination of mRNA Expression Levels in Heart Tissues
Total RNA was extracted from heart tissues by using Trizol reagent, and the obtained RNA was reverse transcribed with HyperScriptTM III RT SuperMix (Xinbei, China), and the polymerase chain reaction was conducted using 2×S6 Universal SYBR qPCR Mix on a 7500 real-time fluorescent quantitative PCR system. GAPDH was utilized as the reference gene in this experiment. The following corresponding primers were used [23]: IL-1β forward 5′-TGCCACCTTTTGACAGTGATGA-3′ and reverse 5′-GAGTGATACTGCCTGCCTGAAG-3'; TNF-α forward 5'-ACCACGCTCTTCTGTCTACTG-3' and reverse 5'-GAGGGTCTGGGGCCATAGAACT-3'; and ICAM-1 forward 5'-TGGGTCGAAGGTGGTTCTTCT-3' and reverse 5'-GTCCAGCCGAGGACCATACAG-3'. Relative gene expression levels were calculated using the 2 - ΔΔCt method [24].
2.8. Western Blot Analysis
Total protein was extracted from heart tissues by using RIPA lysate (EpiZyme, China), and protein concentration was then determined using a bicinchoninic acid kit (Solarbio, China). Following electrophoresis, the samples were transferred to polyvinylidene difluoride (PVDF) membranes, followed by membrane blocking with TBST containing 5% skimmed milk. The membranes were then incubated overnight at 4°C with the following rabbit primary antibodies: HSP90 (1:5000, Proteintech, #13171-1-AP, Wuhan, China), Bcl-2 (1:3000, Signalway Antibody, #40639, Baltimore, MD), Bax (1:2000, Abways, #CY5059, China), C3 (1:3000, Abcam, #EPR19394, Cambridge, UK), C5a (1:2000, ABclonal, #A8104, Wuhan, China), NF-κB p65 (1:5000, Abways, #CY5034, China), and GAPDH (1:2000, Servicebio, #GB15004, Wuhan, China). Horseradish peroxidase-labeled goat anti-rabbit secondary antibodies (1:10000, Proteintech, #SA00001-2, Wuhan, China) were used for 1 h of incubation at room temperature. The signals were captured using e-BLOT Touch Imager Pro, and protein expression was analyzed using ImageJ software [25].
2.9. Statistical Analysis
SPSS 25.0 software was used for statistical analysis of the obtained data. Measurement values were expressed as mean ± standard deviation. Mean values of multiple groups were compared by one-way analysis of variance (ANOVA). Statistical significance was considered at P < 0.05.
3. RESULTS
A total of 120 mice were utilized in this experiment. Four mice died due to ventricular arrhythmia, cardiogenic shock, and respiratory failure: one each in the I/R, VPre + GA, VPost, and VPost + GA groups. Following exclusion and additional analysis, the obtained results were based on the remaining 116 mice.
3.1. Vericiguat Upregulated HSP90 Protein Expression
To determine the role of HSP90 in VPre and VPost treatments, we assessed the protein expression levels of HSP90. The results demonstrated that both VPre and VPost treatments significantly increased HSP90 protein levels compared to that in the I/R group (P < 0.05, Fig. 1). Furthermore, HSP90 protein levels were decreased in the VPre + GA and VPost + GA groups. These findings indicate that VPre and VPost alleviated myocardial I/R injury by upregulating the HSP90 protein expression level.
Fig. (1).

Impacts of VPre and VPost on the protein expression of HSP90. (A) and (B) display representative Western blot results illustrating the expression pattern of HSP90. (C) and (D) present the relative expression levels of HSP90 protein. The data are shown as the mean ± standard deviation. A symbol '@' indicates P < 0.05 when compared with the sham group; '#' represents P < 0.05 versus the I/R group; '&' denotes P < 0.05 in contrast to the VPre group; '$' shows P < 0.05 compared with the VPost group. There are n = 5 animals in each group.
3.2. Vericiguat Ameliorated I/R-induced Myocardial Infarct Size Via HSP90
As shown in Fig. (2), the sham group exhibited no myocardial infarction. The infarct sizes of the VPre and VPost groups were significantly smaller than that of the I/R group (18.38 ± 2.48% vs. 36.61 ± 2.01% and 24 ± 2.15% vs. 36.61 ± 2.01%, all P < 0.05). Conversely, the VPre + GA and VPost + GA groups showed a significant increase in the infarct size (18.38 ± 2.48% vs. 31.67 ± 1.51% and 24 ± 2.15% vs. 36.74 ± 1.43%, all P < 0.05).
Fig. (2).

(A) depicts the impacts of VPre and VPost, both with and without GA, on the infarct size following myocardial I/R injury. (B) shows the quantitative assessment of myocardial infarct size. The outcomes are displayed as the means ± standard deviation. A '#' indicates P < 0.05 when compared with the I/R group; an '&' represents P < 0.05 versus the VPre group; a '$' denotes P < 0.05 compared with the VPost group. There are n = 5 animals in each group.
3.3. Vericiguat Mitigated I/R Injury-induced Cardiomyocyte Apoptosis Through Protective Effects Mediated by HSP90
As depicted in Fig. (3), the I/R group exhibited numerous apoptotic cells, with an apoptosis rate of 59.97 ± 11.11%. The VPre and VPost groups showed significantly reduced apoptosis rates of 15.75 ± 4.32% and 16.53 ± 3.2%, respectively, compared to the I/R group (all P< 0.05). However, GA inhibited the anti-apoptotic effects of VPre and VPost (apoptosis rates for the VPre + GA and VPost + GA groups: 35.45 ± 4.17% and 38.22 ± 5.83%, respectively, all P < 0.05).
Fig. (3).

(A) displays the impacts of VPre and VPost, either with or without GA, on apoptosis following myocardial I/R injury. (B) presents the quantitative analysis of the cell apoptotic rate. The results are shown in a bar graph as the means ± standard deviation. Blue fluorescence represents DAPI staining, while red fluorescence indicates TUNEL staining. The TUNEL-stained images are at a magnification of ×200, and all scale bars are 100 μm. '@' is used to show P < 0.05 in comparison to the sham group; '#' is for P < 0.05 when contrasted with the I/R group; '&' implies P < 0.05 versus the VPre group; '$' denotes P < 0.05 compared with the VPost group. Each group consists of n = 5 samples.
To investigate the mechanisms through which VPre and VPost inhibit apoptosis, we determined the protein expression levels of Bcl-2 and Bax. Compared to the sham group, the I/R group exhibited a notable increase in the Bax protein level, and a marked reduction in the Bcl-2 protein level (P < 0.05, Fig. 4). The VPre and VPost groups demonstrated significantly elevated, Bcl-2 protein levels and downregulated Bax protein levels (P < 0.05). These expression patterns were reversed in the VPre + GA and VPost + GA groups.
Fig. (4).

Impacts of VPre and VPost, either with or without GA, on the protein expression of Bcl-2 and Bax following myocardial I/R injury. (A) and (B) display representative Western blot results illustrating the expression patterns of Bcl-2 and Bax. (C) and (D) present the relative expression levels of Bcl-2 and Bax proteins. The data are shown as the means ± standard deviation. '@' is used to indicate P < 0.05 in comparison to the sham group; '#' is for P < 0.05 when contrasted with the I/R group; '&' implies P < 0.05 versus the VPre group; '$' denotes P < 0.05 compared with the VPost group. Each group consists of n = 5 samples.
3.4. Vericiguat Ameliorated I/R-induced Myocardial Injury Via HSP90
Compared to the sham group, serum levels of CK-MB, LDH, and cTnI were markedly elevated in the I/R group (Table 1). The VPre and VPost groups exhibited a significant reduction in serum levels of CK-MB (744.8 ± 123.6 vs. 1623.2 ± 212.0 and 827.4 ± 161.2 vs. 1623.2 ± 212.0, all P < 0.05), cTnI (22.4 ± 5.9 vs. 70.5 ± 4.7 and 33.6 ± 7.9 vs. 70.5 ± 4.7, all P < 0.05), and LDH (1687.4 ± 75.1 vs. 2982.8 ± 372.2 and 1560.4 ± 309.7 vs. 2982.8 ± 372.2, all P < 0.05) compared to those in the I/R group. These results indicate that VPre and VPost treatments effectively reduced myocardial injury induced by I/R.
Table 1.
Serum levels of cTnI, CK-MB, and LDH in mice.
| Groups | CK-MB (U/L) | LDH (U/L) | cTnI (ng/mL) |
|---|---|---|---|
| Sham | 189.2 ± 43.4 | 528.4 ± 156.7 | 0.04 ± 0.02 |
| I/R | 1623.2 ± 212.0@&$ | 2982.8 ± 372.2@&$ | 70.5 ± 4.7@&$ |
| VPre | 744.8 ± 123.6# | 1687.4 ± 75.1@# | 22.6 ± 5.8@# |
| VPre + GA | 1969.2 ± 491.6@& | 2921.8 ± 351.5@& | 79.6 ± 6.3@& |
| VPost | 827.4 ± 161.2@# | 1560.4 ± 309.7@# | 33.6 ± 7.9@# |
| VPost + GA | 1629.4 ± 289.7@$ | 2823.6 ± 208.0@$ | 70.5 ± 8.4@$ |
Note: The data are shown as the means ± standard deviation. '@' is used to indicate P < 0.05 in comparison to the sham group; '#' is for P < 0.05 when contrasted with the I/R group; '&' implies P < 0.05 versus the VPre group; '$' denotes P < 0.05 compared with the VPost group. Each group consists of n = 5 samples.
3.5. Vericiguat Alleviated I/R-induced Inflammatory Responses Via HSP90
Considering the pivotal role of inflammation in myocardial I/R injury, RT-qPCR was conducted to measure the mRNA expression levels of IL-1β, TNF-α, and ICAM-1. Compared to the I/R group, the sham group displayed a significant decrease in the mRNA expression levels of IL-1β, TNF-α, and ICAM-1 (all P < 0.05, Fig. 5). However, the I/R, VPre + GA, and VPost + GA groups demonstrated significantly higher expression levels of IL-1β, TNF-α, and ICAM-1 compared to the VPre and VPost groups (all P < 0.05).
Fig. (5).

Impacts of VPre and VPost, either with or without GA, on the expression of IL-1β, TNF-α, and ICAM-1 following myocardial I/R injury. The mRNA expression levels of these three genes were determined through RT-qPCR across different groups. The results are presented as the means ± standard deviation. '@' is used to show P < 0.05 in comparison to the sham group; '#' is for P < 0.05 when contrasted with the I/R group; '&' implies P < 0.05 versus the VPre group; '$' denotes P < 0.05 compared with the VPost group. Each group consists of n = 5 samples.
3.6. Vericiguat Mitigated I/R Injury-induced Activation of C3, C5a, and NF-κB Through a HSP90-mediated Mechanism
We evaluated the relationship between HSP90 and the C3, C5a, and NF-κB pathways under VPre and VPost treatments by using the HSP90 inhibitor GA. VPre and VPost treatments decreased the levels of C3, C5a, and NF-κB compared to those in the I/R group (all P < 0.05). GA administration reversed the inhibitory effects of VPre and VPost on C3, C5a, and NF-κB (all P < 0.05, Fig. 6). These findings suggest that HSP90 mediates the cardioprotective effects of VPre and VPost by inhibiting C3 and C5a activation and suppressing NF-κB signaling. The results indicate that VPre and VPost exert their cardioprotective effects by inhibiting complement system activation and NF-κB signaling. Furthermore, these effects of VPre and VPost were closely associated with HSP90 activity.
Fig. (6).

Impacts of VPre and VPost, either with or without GA, on the protein expression of C3, C5a, and NF-κB. (A) and (B) display representative Western blot results illustrating the expression patterns of C3, C5a, and NF-κB. (C) and (D) present the relative expression levels of these three proteins. The values are expressed as the means ± standard deviation. '@' is used to indicate P < 0.05 in comparison to the sham group; '#' is for P < 0.05 when contrasted with the I/R group; '&' implies P < 0.05 versus the VPre group; '$' denotes P < 0.05 compared with the VPost group. Each group consists of n = 5 samples.
4. DISCUSSION
The key finding of the present study is that vericiguat substantially attenuated myocardial I/R injury through HSP90-mediated mechanisms. We demonstrated that vericiguat markedly reduced the infarct area, decreased the extent of cardiomyocyte apoptosis, and lowered serum levels of LDH, CK-MB, and cTnI. Additionally, vericiguat reduced the expression levels of C3, C5a, NF-κB, and Bax and decreased the release of inflammatory factors such as TNF-α, IL-1β, and ICAM-1. Concurrent with these beneficial effects, the expression levels of HSP90 and Bcl-2 were upregulated. However, the introduction of the HSP90 inhibitor GA negated the cardioprotective effects of vericiguat. Thus, these findings highlight the crucial role of HSP90 in vericiguat-induced cardioprotection, potentially through the inhibition of C3, C5a, and NF-κB activation.
Vericiguat, a novel sGC stimulator, is currently utilized for treating heart failure. Based on the largest sGC stimulator clinical trial published to date, vericiguat demonstrated exceptional efficacy in treating heart failure patients with coronary heart disease, which suggests its potential for treating I/R injury [6]. Previous animal studies have demonstrated that vericiguat ameliorates myocardial I/R injury by enhancing microcirculation, promoting angiogenesis, improving autophagy, and exhibiting anti-apoptotic effects [4, 7]. Thus far, few studies have investigated whether vericiguat counteracts myocardial I/R injury through HSP90 during pre- and post-conditioning treatments. Therefore, by utilizing an in vivo I/R mouse model, this study revealed that vericiguat pre- and post-conditioning significantly elevated HSP90 expression to protect the myocardium from I/R injury. However, the HSP90 inhibitor GA reversed vericiguat-induced cardioprotective effects.
Cardiomyocyte apoptosis plays a crucial role in myocardial I/R injury [26-28]. The survival of cardiomyocytes in the ischemic area is dependent on the ratio between the anti-apoptotic protein (Bcl-2) and the pro-apoptotic protein (Bax) [29]. An increase in the Bcl-2 expression level modulates cardiomyocyte apoptosis by inhibiting the synthesis of Bax [30, 31]. We previously reported that an increased Bcl-2 expression level in ischemic postconditioning depended on HSP90; this process was accompanied by reduced Bax expression [22]. Furthermore, previous studies demonstrated that treatment with the HSP90 inhibitor GA blocked the interaction of HSP90 with Bcl-2, thereby promoting mast cell apoptosis [32]. In the present study, we found that combining vericiguat with GA neutralized VPre- and VPost-induced elevation in Bcl-2 expression. This finding implies that the anti-apoptotic effect of vericiguat is closely associated with HSP90 expression.
Complement system activation plays a vital role in the pathogenesis of myocardial I/R injury [9]. Complement components C3 and C5a, generated through the activation of the classical, lectin, and alternative complement system pathways, accumulate in the hypoxic myocardium; these accumulated complement components exacerbate myocardial necrosis and facilitate leukocyte chemotaxis to trigger the release of inflammatory cytokines (ICAM-1, TNF-α, and IL-1β), eventually resulting in myocardial damage [33, 34]. Furthermore, C5a enhances the inflammatory response by activating NF-κB signaling [12]. Besides vericiguat, there are other sGC stimulators such as cinaciguat. Additionally, a previous study reported that praliciguat can decrease the levels of inflammation-related markers in I/R injury [35, 36]. To date, there are few reports on whether vericiguat can protect the myocardium from I/R injury by inhibiting TNF-α, ICAM-1, IL-1β, C3, and C5a. Our findings revealed a reduction in the levels of these inflammatory markers in both VPre and VPost groups compared to those in the I/R group. These results highlight the potential mechanisms through which vericiguat induces inflammatory suppression and cardioprotective effects.
The NF-κB signaling pathway serves an essential function in myocardial I/R injury [37]. As a crucial inflammatory response regulator, it modulates the complement component C3 to enhance complement system-mediated immune-inflammatory response [38, 39]. Additionally, NF-κB promotes the expression of proinflammatory cytokines, responds to complement activation, and exacerbates myocardial injury [12, 40, 41]. However, the interplay between complement components and NF-κB signaling in the cardioprotective effects of vericiguat remains unclear. Our results showed that vericiguat concurrently inhibits NF-κB and complement components C3 and C5a, suggesting a potential link between NF-κB signaling inhibition and complement system regulation.
HSP90 is an endogenous stress protein that primarily functions as a molecular chaperone [42]. As a companion of sGC, HSP90 facilitates the maturity of the precursor into sGC, maintains sGC stability, and enhances the production of cGMP [43-46]. HSP90 significantly contributes to the cardioprotective effects of vericiguat. In response to cellular stress and ischemic damage, the overexpression of HSP90 promotes cell survival and protects the myocardium from I/R injury during ischemic postconditioning and pharmacological conditioning [22, 47, 48]. Therefore, we conducted a study to investigate the relationship between vericiguat and HSP90 in ameliorating myocardial I/R injury. HSP90 protects cells against complement-mediated cell death [49, 50]. Previous research has reported the role of HSP90 in inhibiting C3 and C5a activation, and NF-κB signaling during pre- and post-conditioning [18, 51].
GA, an HSP90 inhibitor, binds to HSP90 and prevents its activity, leading to the degradation of its substrate proteins [52, 53]. Previous studies have shown that GA derivatives, such as 17DMAG, can inhibit HSP90 gene expression [54, 55]. In the present study, GA was utilized to examine the role of HSP90 in inhibiting C3 and C5a activation and NF-κB signaling during vericiguat-induced cardioprotection. The results revealed elevated HSP90 levels and reduced C3, C5a, and NF-κB levels in both VPre and VPost groups. However, GA treatment reversed these beneficial effects of vericiguat. To the best of our knowledge, this study presents the first evidence of the involvement of HSP90 in the inhibition of complement activation by vericiguat, providing a novel perspective for myocardial I/R injury treatment.
These findings substantiate the role of HSP90 in inhibiting C3, C5a, NF-κB, and Bax during VPre and VPost treatments. Furthermore, our observations revealed a novel mechanism of cardioprotective effects of vericiguat, including but not limited to the reduction of myocardial infarct size and cardiomyocyte apoptosis; induction of anti-inflammatory effects; and inhibition of C3, C5a, and NF-κB. To our knowledge, this study demonstrated for the first time the interaction between HSP90, Bcl-2, C3, C5a, NF-κB, and Bax in VPre and VPost treatments, indicating that vericiguat-induced cardioprotective effects are closely linked to HSP90 and the complement system.
5. STUDY LIMITATIONS
The study has some limitations. First, while our data provide preliminary insights into the role of HSP90 in vericiguat-induced cardioprotective mechanisms, additional research is needed to further elucidate the detailed molecular interactions and the involved signaling pathways, as well as to identify broader therapeutic targets of vericiguat in myocardial I/R injury. Second, other heat shock proteins, including HSP70 and HSP60, also participate in vericiguat-induced cardioprotection, and further studies regarding their roles are required. Third, this experiment utilized only the HSP90 inhibitor GA. Future investigations would benefit from exploring the impact of over- or under- expressing HSP90 through viral vectors to obtain a more comprehensive understanding of the role of HSP90 in VPre and VPost treatments.
CONCLUSION
In conclusion, HSP90 plays an essential role in vericiguat-induced cardioprotection against I/R injury, partially by inhibiting complement system activation, NF-κB signaling, and Bax expression, and reducing myocardial inflammation, eventually minimizing I/R-induced myocardial infarct size, cardiomyocyte apoptosis, and myocardial injury. These findings provide novel insights into vericiguat-mediated cardioprotection and suggest potential therapeutic targets for treating I/R injury.
AUTHORS’ CONTRIBUTIONS
The authors confirm their contribution to the paper as follows: Writing the Paper: JC; Data Collection: SP; Writing-Original Draft Preparation: DW; Data Analysis or Interpretation: JM, MW; Writing-Reviewing and Editing: GZ, RT. All authors reviewed the results and approved the final version of the manuscript
LIST OF ABBREVIATIONS
- AMI
Acute myocardial infarction
- ANOVA
Analysis of variance
- cGMP
Cyclic guanosine phosphate
- CK-MB
Creatine kinase-MB
- cTnI
Cardiac troponin I
- GA
Geldanamycin
- HSP90
Heat shock protein 90
- I/R
Ischemia/reperfusion
- ICAM-1
Intercellular cell adhesion factor-1
- IL
Interleukin
- LAD
Left anterior descending
- LDH
Lactate dehydrogenase
- NO
Nitric oxide
- PVDF
Polyvinylidene difluoride
- sGC
Soluble guanylate cyclase
- TNF-α
Tumor necrosis factor-α
- VPost
Vericiguat postconditioning
- VPre
Vericiguat preconditioning
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The experimental protocols were approved by the Animal Protection and Use Committee of Guangxi Medical University, Nanning, China (Approval NO. 202310009).
HUMAN AND ANIMAL RIGHTS
The experimental protocols were performed in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA).
All the procedures involving animals were performed according to the guidelines of the Chinese Committee on Animal Care Use.
This study adheres to internationally accepted standards for animal research, following the 3Rs principle. The ARRIVE guidelines were employed for reporting experiments involving live animals, promoting ethical research practices.
CONSENT FOR PUBLICATION
Not applicable.
AVAILABILITY OF DATA AND MATERIALS
All data generated or analyzed during this study are included in this published article.
FUNDING
This study was supported by grants from the Natural Science Foundation of Guangxi Province (No. 2020GXNSFAA297135).
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
ACKNOWLEDGEMENTS
The authors would like to thank TopEdit (www.topeditsci.com) for its linguistic assistance during the preparation of this manuscript.
REFERENCES
- 1.Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173–95. doi: 10.1016/j.jacc.2007.09.011. [DOI] [PubMed] [Google Scholar]
- 2.Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi: 10.1016/S0140-6736(14)61682-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Davidson S.M., Ferdinandy P., Andreadou I., et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2019;73(1):89–99. doi: 10.1016/j.jacc.2018.09.086. [DOI] [PubMed] [Google Scholar]
- 4.Cai Y., Zhang B., Shalamu A., Gao T., Ge J. Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation. Ann Transl Med. 2022;10(12):662. doi: 10.21037/atm-22-2583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Armstrong P.W., Pieske B., Anstrom K.J., et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–93. doi: 10.1056/NEJMoa1915928. [DOI] [PubMed] [Google Scholar]
- 6.Saldarriaga C., Atar D., Stebbins A., et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022;24(5):782–90. doi: 10.1002/ejhf.2468. [DOI] [PubMed] [Google Scholar]
- 7.Zhu W., Ben Y., Shen Y., Liu W. Vericiguat protects against cardiac damage in a pig model of ischemia/reperfusion. PLoS One. 2023;18(12):0295566. doi: 10.1371/journal.pone.0295566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Panagiotou A., Trendelenburg M., Osthoff M. The lectin pathway of complement in myocardial ischemia/reperfusion injury—Review of its significance and the potential impact of therapeutic interference by C1 Esterase inhibitor. Front Immunol. 2018;9:1151. doi: 10.3389/fimmu.2018.01151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Vogel C.W. The role of complement in myocardial infarction reperfusion injury: An underappreciated therapeutic target. Front Cell Dev Biol. 2020;8:606407. doi: 10.3389/fcell.2020.606407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Han H., Dong P., Liu K. The role of NF-κB in myocardial ischemia/reperfusion injury. Curr Protein Pept Sci. 2022;23(8):535–47. doi: 10.2174/1389203723666220817085941. [DOI] [PubMed] [Google Scholar]
- 11.Pluijmert N.J., Atsma D.E., Quax P.H.A. Post-ischemic myocardial inflammatory response: A complex and dynamic process susceptible to immunomodulatory therapies. Front Cardiovasc Med. 2021;8:647785. doi: 10.3389/fcvm.2021.647785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Zhang X.Y., Liu Y., He T., et al. Anaphylatoxin C5a induces inflammation and reduces insulin sensitivity by activating TLR4/NF-kB/PI3K signaling pathway in 3T3-L1 adipocytes. Biomed Pharmacother. 2018;103:955–64. doi: 10.1016/j.biopha.2018.04.057. [DOI] [PubMed] [Google Scholar]
- 13.Aceros H., Der Sarkissian S., Borie M., Stevens L.M., Mansour S., Noiseux N. Celastrol-type HSP90 modulators allow for potent cardioprotective effects. Life Sci. 2019;227:8–19. doi: 10.1016/j.lfs.2019.04.025. [DOI] [PubMed] [Google Scholar]
- 14.Peng C., Zhao F., Li H., Li L., Yang Y., Liu F. HSP90 mediates the connection of multiple programmed cell death in diseases. Cell Death Dis. 2022;13(11):929. doi: 10.1038/s41419-022-05373-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Amour J., Brzezinska A.K., Weihrauch D., et al. Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology. 2009;110(2):317–25. doi: 10.1097/ALN.0b013e3181942cb4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Vladic N., Ge Z.D., Leucker T., et al. Decreased tetra-hydrobiopterin and disrupted association of Hsp90 with eNOS by hyperglycemia impair myocardial ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2011;301(5):H2130–9. doi: 10.1152/ajpheart.01078.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wang D.X., Huang Z., Li Q.J., et al. Involvement of HSP90 in ischemic postconditioning-induced cardioprotection by inhibition of the complement system, JNK and inflammation. Acta Cir Bras. 2020;35(1):202000105. doi: 10.1590/s0102-865020200010000005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.He S.T., Wang D.X., Meng J.J., et al. HSP90-mediates liraglutide preconditioning-induced cardioprotection by inhibiting C5a and NF-κB. J Invest Surg. 2022;35(5):1012–20. doi: 10.1080/08941939.2021.1989729. [DOI] [PubMed] [Google Scholar]
- 19.Wang D., He S., Zhong G., Meng J., Bi Q., Tu R. Effects of heat shock protein 90 on complement activation in myocardial ischemia/reperfusion injury after pioglitazone preconditioning. Adv Clin Exp Med. 2023;32(12):1401–12. doi: 10.17219/acem/162578. [DOI] [PubMed] [Google Scholar]
- 20.Chen T., Kong B., Shuai W., Gong Y., Zhang J., Huang H. Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling. Life Sci. 2023;334:122184. doi: 10.1016/j.lfs.2023.122184. [DOI] [PubMed] [Google Scholar]
- 21.Janssen W., Schwarz T., Bütehorn U., et al. Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats. Xenobiotica. 2022;52(5):453–62. doi: 10.1080/00498254.2022.2082899. [DOI] [PubMed] [Google Scholar]
- 22.Zhong G.Q., Tu R.H., Zeng Z.Y., et al. Novel functional role of heat shock protein 90 in protein kinase C-mediated ischemic postconditioning. J Surg Res. 2014;189(2):198–206. doi: 10.1016/j.jss.2014.01.038. [DOI] [PubMed] [Google Scholar]
- 23.Singh C., Roy-Chowdhuri S. Quantitative real-time PCR: Recent advances. Methods Mol Biol. 2016;1392:161–76. doi: 10.1007/978-1-4939-3360-0_15. [DOI] [PubMed] [Google Scholar]
- 24.Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) Method. Methods. 2001;25(4):402–8. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 25.Zhang X.Y., Huang Z., Li Q.J., et al. Role of HSP90 in suppressing TLR4-mediated inflammation in ischemic postconditioning. Clin Hemorheol Microcirc. 2020;76(1):51–62. doi: 10.3233/CH-200840. [DOI] [PubMed] [Google Scholar]
- 26.Eefting F., Rensing B., Wigman J., et al. Role of apoptosis in reperfusion injury. Cardiovasc Res. 2004;61(3):414–26. doi: 10.1016/j.cardiores.2003.12.023. [DOI] [PubMed] [Google Scholar]
- 27.Wang H., Pang W., Xu X., You B., Zhang C., Li D. Cryptotanshinone attenuates ischemia/reperfusion-induced apoptosis in myocardium by upregulating MAPK3. J Cardiovasc Pharmacol. 2021;77(3):370–7. doi: 10.1097/FJC.0000000000000971. [DOI] [PubMed] [Google Scholar]
- 28.Saraste A., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., Voipio-Pulkki L.M. Apoptosis in human acute myocardial infarction. Circulation. 1997;95(2):320–323. doi: 10.1161/01.CIR.95.2.320. [DOI] [PubMed] [Google Scholar]
- 29.Li J., Wang S., Huang S., Shao W., Zhang J. Remifentanil anesthesia on the expression of apoptosis-related proteins Bcl-2 and Bax in rat myocardial cells with ischemia-reperfusion injury. Cell Mol Biol. 2022;67(5):96–103. doi: 10.14715/cmb/2021.67.5.13. [DOI] [PubMed] [Google Scholar]
- 30.Korshunova A., Blagonravov M., Neborak E., et al. BCL2-regulated apoptotic process in myocardial ischemia-reperfusion injury (Review). Int J Mol Med. 2020;47(1):23–36. doi: 10.3892/ijmm.2020.4781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Zhu X., Li S., Huang C., Huang G., Xu J. LncRNA CRNDE inhibits cardiomyocytes apoptosis by YAP1 in myocardial ischaemia/reperfusion injury. Autoimmunity. 2021;54(4):204–12. doi: 10.1080/08916934.2021.1913580. [DOI] [PubMed] [Google Scholar]
- 32.Cohen-Saidon C., Carmi I., Keren A., Razin E. Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90β. Blood. 2006;107(4):1413–20. doi: 10.1182/blood-2005-07-2648. [DOI] [PubMed] [Google Scholar]
- 33.Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res. 1998;83(8):860–9. doi: 10.1161/01.RES.83.8.860. [DOI] [PubMed] [Google Scholar]
- 34.Imanaka-Yoshida K. Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy. Pathol Int. 2020;70(1):1–11. doi: 10.1111/pin.12868. [DOI] [PubMed] [Google Scholar]
- 35.Salloum F.N., Das A., Samidurai A., et al. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: Role of hydrogen sulfide. Am J Physiol Heart Circ Physiol. 2012;302(6):H1347–54. doi: 10.1152/ajpheart.00544.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Mace E.H., Kimlinger M.J., Billings F.T. Targeting soluble guanylyl cyclase during ischemia and reperfusion. Cells. 2023;12(14):1903. doi: 10.3390/cells12141903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Yao Y., Li F., Zhang M., et al. Targeting CaMKII-δ9 ameliorates cardiac ischemia/reperfusion injury by inhibiting myocardial inflammation. Circ Res. 2022;130(6):887–903. doi: 10.1161/CIRCRESAHA.121.319478. [DOI] [PubMed] [Google Scholar]
- 38.Nitkiewicz J., Borjabad A., Morgello S. HIV induces expression of complement component C3 in astrocytes by NF-κB-dependent activation of interleukin-6 synthesis. J Neuroinflammation. 2017;14(1):23. doi: 10.1186/s12974-017-0794-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Liu M., Wang H., Zhang J., et al. NF-κB signaling pathway-enhanced complement activation mediates renal injury in trichloroethylene-sensitized mice. J Immunotoxicol. 2018;15(1):63–72. doi: 10.1080/1547691X.2017.1420712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Oliveira J.B., Soares A.A.S.M., Sposito A.C. Inflammatory response during myocardial infarction. Adv Clin Chem. 2018;84:39–79. doi: 10.1016/bs.acc.2017.12.002. [DOI] [PubMed] [Google Scholar]
- 41.Tang B., Ma J., Ha X., Zhang Y., Xing Y. Tumor necrosis factor-alpha upregulated PHLPP1 through activating nuclear factor-kappa B during myocardial ischemia/reperfusion. Life Sci. 2018;207:355–63. doi: 10.1016/j.lfs.2018.06.023. [DOI] [PubMed] [Google Scholar]
- 42.Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11(7):515–28. doi: 10.1038/nrm2918. [DOI] [PubMed] [Google Scholar]
- 43.Stuehr D.J., Misra S., Dai Y., Ghosh A. Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase. J Biol Chem. 2021;296:100336. doi: 10.1016/j.jbc.2021.100336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Papapetropoulos A., Zhou Z., Gerassimou C., et al. Interaction between the 90-kDa heat shock protein and soluble guanylyl cyclase: Physiological significance and mapping of the domains mediating binding. Mol Pharmacol. 2005;68(4):1133–41. doi: 10.1124/mol.105.012682. [DOI] [PubMed] [Google Scholar]
- 45.Venema R.C., Venema V.J., Ju H., et al. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2003;285(2):H669–78. doi: 10.1152/ajpheart.01025.2002. [DOI] [PubMed] [Google Scholar]
- 46.Nedvetsky P.I., Meurer S., Opitz N., Nedvetskaya T.Y., Müller H., Schmidt H.H.H.W. Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase. FEBS Lett. 2008;582(2):327–331. doi: 10.1016/j.febslet.2007.12.025. [DOI] [PubMed] [Google Scholar]
- 47.Cheng X.F., He S.T., Zhong G.Q., et al. Exosomal HSP90 induced by remote ischemic preconditioning alleviates myocardial ischemia/reperfusion injury by inhibiting complement activation and inflammation. BMC Cardiovasc Disord. 2023;23(1):58. doi: 10.1186/s12872-023-03043-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Wang M., Sun G., Du Y., et al. Myricitrin protects cardiomyocytes from hypoxia/reoxygenation injury: Involvement of heat shock protein 90. Front Pharmacol. 2017;8:353. doi: 10.3389/fphar.2017.00353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Sreedhar A.S., Mihály K., Pató B., et al. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J Biol Chem. 2003;278(37):35231–40. doi: 10.1074/jbc.M301371200. [DOI] [PubMed] [Google Scholar]
- 50.Sreedhar A.S., Nardai G., Csermely P. Enhancement of complement-induced cell lysis: A novel mechanism for the anticancer effects of Hsp90 inhibitors. Immunol Lett. 2004;92(1-2):157–61. doi: 10.1016/j.imlet.2003.11.025. [DOI] [PubMed] [Google Scholar]
- 51.Tu R.H., Wang D.X., Zhong G.Q., et al. New targets of morphine postconditioning protection of the myocardium in ischemia/reperfusion injury: Involvement of HSP90/Akt and C5a/NF-κB. Open Med. 2021;16(1):1552–63. doi: 10.1515/med-2021-0340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell. 1997;89(2):239–50. doi: 10.1016/S0092-8674(00)80203-2. [DOI] [PubMed] [Google Scholar]
- 53.Prodromou C., Roe S.M., O’Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell. 1997;90(1):65–75. doi: 10.1016/S0092-8674(00)80314-1. [DOI] [PubMed] [Google Scholar]
- 54.Sun X., Bristol J.A., Iwahori S., et al. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol. 2013;87(18):10126–38. doi: 10.1128/JVI.01671-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Mellatyar H., Talaei S., Nejati-Koshki K., Akbarzadeh A. Targeting HSP90 gene expression with 17-DMAG nanoparticles in breast cancer cells. Asian Pac J Cancer Prev. 2016;17(5):2453–7. [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
